Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vtesse, Inc.
Biopharma Quarterly Deal-making Statistics, Q4 2017
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.
Mallinckrodt Reduces Acthar Reliance With $1.2bn Sucampo Buy
Mallinckrodt is to acquire Sucampo Pharmaceuticals for about $1.2bn. The deal brings it a short-term sales boost from Amitiza, although the constipation treatment only has a few years left before generic competition hits. Longer-term hopes lie in two Phase III products for rare diseases.
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.
Start-Up Quarterly Statistics: Private And Public Firms Were Prolific Fundraisers
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.